Cargando…

Assessing the Potency of the Novel Tocolytics 2-APB, Glycyl-H-1152, and HC-067047 in Pregnant Human Myometrium

The intracellular signaling pathways that regulate myometrial contractions can be targeted by drugs for tocolysis. The agents, 2-APB, glycyl-H-1152, and HC-067047, have been identified as inhibitors of uterine contractility and may have tocolytic potential. However, the contraction-blocking potency...

Descripción completa

Detalles Bibliográficos
Autores principales: Hossain, Md Reduanul, Tolosa, Jorge M., Young, Roger C., Smith, Roger, Paul, Jonathan W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810572/
https://www.ncbi.nlm.nih.gov/pubmed/35715551
http://dx.doi.org/10.1007/s43032-022-01000-2
_version_ 1784863336248115200
author Hossain, Md Reduanul
Tolosa, Jorge M.
Young, Roger C.
Smith, Roger
Paul, Jonathan W.
author_facet Hossain, Md Reduanul
Tolosa, Jorge M.
Young, Roger C.
Smith, Roger
Paul, Jonathan W.
author_sort Hossain, Md Reduanul
collection PubMed
description The intracellular signaling pathways that regulate myometrial contractions can be targeted by drugs for tocolysis. The agents, 2-APB, glycyl-H-1152, and HC-067047, have been identified as inhibitors of uterine contractility and may have tocolytic potential. However, the contraction-blocking potency of these novel tocolytics was yet to be comprehensively assessed and compared to agents that have seen greater scrutiny, such as the phosphodiesterase inhibitors, aminophylline and rolipram, or the clinically used tocolytics, nifedipine and indomethacin. We determined the IC(50) concentrations (inhibit 50% of baseline contractility) for 2-APB, glycyl-H-1152, HC-067047, aminophylline, rolipram, nifedipine, and indomethacin against spontaneous ex vivo contractions in pregnant human myometrium, and then compared their tocolytic potency. Myometrial strips obtained from term, not-in-labor women, were treated with cumulative concentrations of the contraction-blocking agents. Comprehensive dose–response curves were generated. The IC(50) concentrations were 53 µM for 2-APB, 18.2 µM for glycyl-H-1152, 48 µM for HC-067047, 318.5 µM for aminophylline, 4.3 µM for rolipram, 10 nM for nifedipine, and 59.5 µM for indomethacin. A single treatment with each drug at the determined IC(50) concentration was confirmed to reduce contraction performance (AUC) by approximately 50%. Of the three novel tocolytics examined, glycyl-H-1152 was the most potent inhibitor. However, of all the drugs examined, the overall order of contraction-blocking potency in decreasing order was nifedipine > rolipram > glycyl-H-1152 > HC-067047 > 2-APB > indomethacin > aminophylline. These data provide greater insight into the contraction-blocking properties of some novel tocolytics, with glycyl-H-1152, in particular, emerging as a potential novel tocolytic for preventing preterm birth. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s43032-022-01000-2.
format Online
Article
Text
id pubmed-9810572
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-98105722023-01-05 Assessing the Potency of the Novel Tocolytics 2-APB, Glycyl-H-1152, and HC-067047 in Pregnant Human Myometrium Hossain, Md Reduanul Tolosa, Jorge M. Young, Roger C. Smith, Roger Paul, Jonathan W. Reprod Sci Pregnancy: Original Article The intracellular signaling pathways that regulate myometrial contractions can be targeted by drugs for tocolysis. The agents, 2-APB, glycyl-H-1152, and HC-067047, have been identified as inhibitors of uterine contractility and may have tocolytic potential. However, the contraction-blocking potency of these novel tocolytics was yet to be comprehensively assessed and compared to agents that have seen greater scrutiny, such as the phosphodiesterase inhibitors, aminophylline and rolipram, or the clinically used tocolytics, nifedipine and indomethacin. We determined the IC(50) concentrations (inhibit 50% of baseline contractility) for 2-APB, glycyl-H-1152, HC-067047, aminophylline, rolipram, nifedipine, and indomethacin against spontaneous ex vivo contractions in pregnant human myometrium, and then compared their tocolytic potency. Myometrial strips obtained from term, not-in-labor women, were treated with cumulative concentrations of the contraction-blocking agents. Comprehensive dose–response curves were generated. The IC(50) concentrations were 53 µM for 2-APB, 18.2 µM for glycyl-H-1152, 48 µM for HC-067047, 318.5 µM for aminophylline, 4.3 µM for rolipram, 10 nM for nifedipine, and 59.5 µM for indomethacin. A single treatment with each drug at the determined IC(50) concentration was confirmed to reduce contraction performance (AUC) by approximately 50%. Of the three novel tocolytics examined, glycyl-H-1152 was the most potent inhibitor. However, of all the drugs examined, the overall order of contraction-blocking potency in decreasing order was nifedipine > rolipram > glycyl-H-1152 > HC-067047 > 2-APB > indomethacin > aminophylline. These data provide greater insight into the contraction-blocking properties of some novel tocolytics, with glycyl-H-1152, in particular, emerging as a potential novel tocolytic for preventing preterm birth. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s43032-022-01000-2. Springer International Publishing 2022-06-17 /pmc/articles/PMC9810572/ /pubmed/35715551 http://dx.doi.org/10.1007/s43032-022-01000-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Pregnancy: Original Article
Hossain, Md Reduanul
Tolosa, Jorge M.
Young, Roger C.
Smith, Roger
Paul, Jonathan W.
Assessing the Potency of the Novel Tocolytics 2-APB, Glycyl-H-1152, and HC-067047 in Pregnant Human Myometrium
title Assessing the Potency of the Novel Tocolytics 2-APB, Glycyl-H-1152, and HC-067047 in Pregnant Human Myometrium
title_full Assessing the Potency of the Novel Tocolytics 2-APB, Glycyl-H-1152, and HC-067047 in Pregnant Human Myometrium
title_fullStr Assessing the Potency of the Novel Tocolytics 2-APB, Glycyl-H-1152, and HC-067047 in Pregnant Human Myometrium
title_full_unstemmed Assessing the Potency of the Novel Tocolytics 2-APB, Glycyl-H-1152, and HC-067047 in Pregnant Human Myometrium
title_short Assessing the Potency of the Novel Tocolytics 2-APB, Glycyl-H-1152, and HC-067047 in Pregnant Human Myometrium
title_sort assessing the potency of the novel tocolytics 2-apb, glycyl-h-1152, and hc-067047 in pregnant human myometrium
topic Pregnancy: Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810572/
https://www.ncbi.nlm.nih.gov/pubmed/35715551
http://dx.doi.org/10.1007/s43032-022-01000-2
work_keys_str_mv AT hossainmdreduanul assessingthepotencyofthenoveltocolytics2apbglycylh1152andhc067047inpregnanthumanmyometrium
AT tolosajorgem assessingthepotencyofthenoveltocolytics2apbglycylh1152andhc067047inpregnanthumanmyometrium
AT youngrogerc assessingthepotencyofthenoveltocolytics2apbglycylh1152andhc067047inpregnanthumanmyometrium
AT smithroger assessingthepotencyofthenoveltocolytics2apbglycylh1152andhc067047inpregnanthumanmyometrium
AT pauljonathanw assessingthepotencyofthenoveltocolytics2apbglycylh1152andhc067047inpregnanthumanmyometrium